Velban

(vinblastine)

ApprovedSmall molecule

Vinblastine is a chemotherapy drug used to treat various types of cancer, including lymphoma and testicular cancer, by stopping cancer cells from dividing and growing.[2] Velban is currently approved and in use across 22 indications[4].[1]

Velban is one of 445 small molecule programs targeting Urinary Bladder Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

444

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Urinary Bladder CarcinomaApproved

ParagangliomaApproved

Lung CancerApproved

LymphomaApproved

Germ Cell TumorActive, not recruiting

Metastatic MelanomaActive, not recruiting

Hodgkins LymphomaApproved

StrictureApproved

Precursor B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Classic Hodgkin LymphomaActive, not recruiting

Urinary Bladder CarcinomaApproved

Approved

ParagangliomaApproved

Approved

Lung CancerApproved

Approved

LymphomaApproved

Approved

Germ Cell TumorPhase 3

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Hodgkins LymphomaApproved

Approved

StrictureApproved

Approved

Precursor B-Cell Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Classic Hodgkin LymphomaPhase 2

Active, not recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

Eli Lilly

Approved

34 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Nuvigil

NNuvo Research GmbH

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Low Grade Glioma

NCT02840409

Phase 2Active, not recruiting

Urothelial Carcinoma

NCT05137262

Q4 2026

Phase 2Active, not recruiting

Lymphoma

NCT03407144

Phase 2Active, not recruiting

Lymphoma

NCT03517137

Phase 3Recruiting

Lymphoma

NCT04638790

Q1 2027

Phase 1/2Active, not recruiting

Chemotherapy

NCT03585465

Clinical

Trials by Indication[1]

Lymphoma34 trials

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Active, not recruiting· Takeda logo

Takeda·Phase 1/2·NCT02979522·59 enrolled

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Recruiting· Takeda logo

Takeda·Phase 4·NCT06831370·124 enrolled

Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00086801·104 enrolled

Show 31 more trials

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05008224·146 enrolled

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

Recruiting·SState Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia·Phase 3·NCT04638790·300 enrolled

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT03407144·340 enrolled

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Unknown status·NNorthwestern University·Phase 2·NCT01476410·48 enrolled

Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02414568·90 enrolled

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

Completed·CCanadian Cancer Trials Group·Phase 1·NCT02343718·7 enrolled

Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00369681·51 enrolled

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Completed· Takeda logo

Takeda·Phase 3·NCT01712490·1,334 enrolled

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Completed·UUniversity of Washington·Phase 1/2·NCT03331341·50 enrolled

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03517137·150 enrolled

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT01390584·6 enrolled

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Recruiting·UUniversity of Virginia·Phase 2·NCT05404945·44 enrolled

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT03646123·255 enrolled

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02292979·170 enrolled

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT03004833·110 enrolled

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03755804·232 enrolled

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003389·854 enrolled

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Completed·FFondazione Michelangelo·Phase 3·NCT01251107·331 enrolled

Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma

Completed·UUniversity of Cologne·Phase 1/2·NCT00147875·60 enrolled

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

Unknown status·KKing Abdullah International Medical Research Center·Phase 2·NCT03527628·220 enrolled

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Active, not recruiting·—·Phase 2·NCT03233347·82 enrolled

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

Completed·SStanford University·Phase 2·NCT00002715·50 enrolled

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02181738·294 enrolled

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06377566·71 enrolled

Prospective Study on HIV-related Hodgkin Lymphoma

Unknown status·HHarlachinger Krebshilfe e.V.·Phase 2·NCT01468740·130 enrolled

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03033914·82 enrolled

PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma

Terminated·UUniversity of Cologne·Phase 2·NCT00512980

Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

Completed·UUniversity of Cologne·Phase 1·NCT01056679·30 enrolled

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Completed· Pfizer logo

Pfizer·Phase 1·NCT01060904·51 enrolled

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01771107·41 enrolled

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00352027·81 enrolled

Bladder Cancer8 trials

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06960577·150 enrolled

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT02710734·78 enrolled

Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

Terminated·KKyoto University·Phase 2·NCT00516750·100 enrolled

Show 5 more trials

4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer

Terminated·SSWOG Cancer Research Network·Phase 3·NCT00005047·521 enrolled

Drug Screening Using IMD in Bladder Cancer

Unknown status·—·Phase 1·NCT06204614·18 enrolled

Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00635726·41 enrolled

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Terminated·SStanford University·Phase 2·NCT03912818·7 enrolled

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT02177695·237 enrolled

Classic Hodgkin Lymphoma4 trials

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

Recruiting·NNational Medical Research Radiological Centre of the Ministry of Health of Russia·Phase 2·NCT06984146·54 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00654732·58 enrolled

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Active, not recruiting·—·Phase 2·NCT03712202·155 enrolled

Show 1 more trial

A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients With Classical Hodgkin Lymphoma, Including Elderly Patients.

Active, not recruiting·NNorthwestern University·Phase 2·NCT06164275·30 enrolled

Hodgkin's Disease4 trials

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00038558·25 enrolled

SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease

Completed·SSWOG Cancer Research Network·Phase 3·NCT00002495·348 enrolled

Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

Terminated·SStanford University·Phase 2·NCT00225173·45 enrolled

Show 1 more trial

Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002561·405 enrolled

Low Grade Glioma3 trials

Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

Active, not recruiting·TThe Hospital for Sick Children·Phase 2·NCT02840409·109 enrolled

Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

Recruiting·UUniversity Hospital, Strasbourg, France·Phase 2·NCT05180825·134 enrolled

Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Recruiting·DDaniel Morgenstern·Phase 1·NCT06381570·57 enrolled

25 more indications

Melanoma3 trials

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

Completed·—·Phase 1·NCT00498979·22 enrolled

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002882·140 enrolled

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00006237·432 enrolled

Prostate Cancer3 trials

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002855·306 enrolled

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT00024167·265 enrolled

Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00003084·75 enrolled

Metastatic Melanoma2 trials

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003027·482 enrolled

Metronomic Therapy in Patients With Metastatic Melanoma

Terminated·—·Phase 2·NCT01542255·7 enrolled

Age2 trials

HD11 for Intermediate Stages

Completed·UUniversity of Cologne·Phase 3·NCT00264953·1,395 enrolled

HD10 for Early Stages

Completed·UUniversity of Cologne·Phase 3·NCT00265018·1,370 enrolled

Urothelial Carcinoma2 trials

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05137262·12 enrolled

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Completed·—·Phase 2·NCT00808639·39 enrolled

Vinblastine2 trials

Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT01884922·35 enrolled

Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT01887522·144 enrolled

Germ Cell Tumor1 trial

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00072215·1 enrolled

Advanced Cancer1 trial

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003376·330 enrolled

Methotrexate1 trial

Vinblastine and Methotrexate in Children With Pulmonary Vein Stenosis

Completed·—·Phase 2·NCT00215046·28 enrolled

Elderly Patients1 trial

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL

Completed·FFondazione Italiana Linfomi - ETS·Phase 3·NCT01148446·226 enrolled

Chemotherapy1 trial

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors

Active, not recruiting·CCentre Oscar Lambret·Phase 1/2·NCT03585465·63 enrolled

Renal Cancer1 trial

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001570·46 enrolled

Langerhans Cell Histiocytosis1 trial

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Recruiting·NNorth American Consortium for Histiocytosis·Phase 2/3·NCT02205762·1,400 enrolled

Plexiform Neurofibroma1 trial

Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas

Completed·—·Phase 2·NCT00030264·23 enrolled

Urothelial Cancer1 trial

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Withdrawn·UUniversity of Southern California·Phase 2·NCT01639521

Urinary Tract Cancer1 trial

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Completed·EECOG-ACRIN Cancer Research Group·Phase 2·NCT02412670·36 enrolled

Non-Small Cell Lung Cancer1 trial

Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT01134861·610 enrolled

Stem Cell Transplantation1 trial

S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

Terminated·SSWOG Cancer Research Network·Phase 3·NCT00005090·11 enrolled

Newly Diagnosed1 trial

Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis

Unknown status·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT05062278·46 enrolled

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01700946·80 enrolled

Metastatic Renal Cell Cancer1 trial

A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00520403·25 enrolled

Relapsed/Refractory1 trial

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Active, not recruiting·NNew York Medical College·Phase 2·NCT07013565·20 enrolled

Advanced Hodgkin Lymphoma1 trial

A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma

Recruiting·UUniversity of Washington·Phase 2·NCT06745076·125 enrolled

Hodgkin Lymphoma1 trial

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Recruiting·UUniversity College, London·Phase 3·NCT04685616·1,042 enrolled

Unspecified2 trials

FIL Study on ABVD DD-DI as Upfront Therapy in HL.

Completed·FFondazione Italiana Linfomi - ETS·Phase 3·NCT03159897·500 enrolled

Rituximab and ABVD for Hodgkin's Patients

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00504504·85 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

VELBAN

NDA NDA012665

Sources

References

[1]
ClinicalTrials.gov — 87 trial records for vinblastine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Velban drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — vinblastine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for vinblastine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA012665). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tubulin Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Eli Lilly

Velban

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Trials by Indication[1]

Lymphoma34 trials

Bladder Cancer8 trials

Classic Hodgkin Lymphoma4 trials

Hodgkin's Disease4 trials

Low Grade Glioma3 trials

Melanoma3 trials

Prostate Cancer3 trials

Metastatic Melanoma2 trials

Age2 trials

Urothelial Carcinoma2 trials

Vinblastine2 trials

Germ Cell Tumor1 trial

Advanced Cancer1 trial

Methotrexate1 trial

Elderly Patients1 trial

Chemotherapy1 trial

Renal Cancer1 trial

Langerhans Cell Histiocytosis1 trial

Plexiform Neurofibroma1 trial

Urothelial Cancer1 trial

Urinary Tract Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Stem Cell Transplantation1 trial

Newly Diagnosed1 trial

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Metastatic Renal Cell Cancer1 trial

Relapsed/Refractory1 trial

Advanced Hodgkin Lymphoma1 trial

Hodgkin Lymphoma1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News